Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
SMTC enters its October 15 earnings release with a quietly interesting setup: the analyst community has been raising targets all week, yet options markets are the most defensive they have been in months.
Stifel lifted its target to $220 from $188 on October 5, keeping its Buy rating. Oppenheimer went further, raising to $225 from $200 on October 1 with an Outperform. These are the two most recent moves, and both lift above the current price of $187.30. The consensus target sits near $212, implying roughly 13% upside from here. At the bullish extreme, Baird holds a $300 target following the August earnings beat, while Morgan Stanley's Equal-Weight with a $195 target captures the cautious fringe. The Street is not uniform, but the direction of travel has been firmly upward.
Options positioning tells a more guarded story heading into the print. The put/call ratio jumped to 0.72 on October 9, nearly two standard deviations above its 20-day average of 0.63. That is not an extreme reading on an absolute basis, but the move is sharp and recent. The ratio had been running consistently below 0.62 for most of September. That shift in the last week, as traders add downside protection ahead of October 15, sits in contrast to the constructive analyst tone.
Short interest offers little drama. At roughly 7.9% of free float, it is a real position worth watching, but it has edged down about 2% over the past week and is off nearly 3% over the past month. There is clearly no conviction build on the short side going into earnings. The borrow market confirms the same: availability is extraordinarily loose at around 2,400% of current short interest, meaning roughly 90 million shares remain available to borrow against the 7.3 million currently shorted. Cost to borrow is 0.47%, up about 10% on the week but still low in absolute terms. Nothing in the lending market suggests a squeeze is forming or that shorts are under pressure to cover.
The fundamental debate going into October 15 is familiar from the August print. Bulls point to the Infrastructure segment's 25% year-over-year growth, record Data Center revenues from FiberEdge ICs, and a 61.7% gross margin. Management has signalled data centre revenue growth above 50% year-over-year for fiscal 2027 as 1.6T FiberEdge ramps. Bears flag the 13% quarter-on-quarter drop in the high-end consumer segment and flat industrial guidance as signs that the growth story is narrowly concentrated. EPS momentum over 90 days ranks in the 92nd percentile, a standout factor score. The 12-month forward EPS growth rank sits much lower, at the 22nd percentile, suggesting analysts see strong near-term numbers but are less enthused about the longer runway. The PE multiple is around 35 times trailing earnings, up roughly 3 points over the past month as the stock rallied 15%.
The most notable ownership development is that BlackRock filed a fresh 13G/A in September, lifting its disclosed stake to 10.0% of shares. That makes it the dominant institutional holder by a wide margin. As always with 13D/G disclosures, the stake is as last reported and may have moved since. On the insider side, the CEO and CFO both executed planned 10b5-1 sales in early October, routine in character. One item worth noting: director Rodolpho Cardenuto sold just under 5,400 shares at $165 on September 16 without a 10b5-1 plan on file, a discretionary sale near the recent range lows. Net insider activity over the past 90 days is negative at roughly minus $4.5 million in value, though most of that reflects the structured selling programs.
The last earnings print, on August 25, produced a 16% one-day gain. That establishes a high bar for implied move expectations going into October 15. The question is less whether data centre momentum is intact and more whether the consumer and industrial drags have stabilised enough to support the re-rated multiple.
See the live data behind this article on ORTEX.
Open SMTC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
